Moderna, Inc. 4

Chief Legal Officer Shannon Thyme Klinger exercised options, received RSU shares, and sold Moderna (MRNA) common stock (including tax-withholding and 10b5-1 sales) on September 1, 2026, for a net reduction in her direct holdings.

On September 1, 2026, Moderna, Inc. Chief Legal Officer Shannon Thyme Klinger exercised 3,471 stock options at $30.96 per share and simultaneously sold 3,471 shares at $139.95 per share pursuant to a Rule 10b5-1 trading plan, realizing an implied spread of roughly $109 per share, while also acquiring 2,166 shares upon the vesting of restricted stock units and disposing of 1,048 shares to cover related tax withholding at $140.34 per share. These transactions reflect a mix of routine equity compensation events (option exercise and RSU vesting) and a planned sale, resulting in a net decrease in directly held common shares from 77,600 to 74,129 and leaving Klinger with substantial continuing ownership in the company.

Filing Facts

CIK

1682852

Ticker

MRNA

Form

4

Source Type

fda

Accession

0001682852-26-000167

Alert Tier

8